PHAT Pengajuan SEC - Phathom Pharmaceuticals, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1783183

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Phathom Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 7, 2025	10-Q	10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTI
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 PHATHOM PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
August 7, 2025	EX-10.3	Employment Letter Agreement, dated June 4, 2025, by and between Anne Marie Cook and the Registrant Exhibit 10.3 June 4, 2025 Anne Marie Cook Re: Employment Offer Letter Dear Anne Marie, Phathom Pharmaceuticals, Inc. (the “Company”) is pleased to offer you a position on the terms set forth in this letter (this “Agreement”). • Start Date. We expect that your employment start date (the “Start Date”) will occur on or about June 23, 2025. • Employment Terms. o Duties; Location. Following the Start D
August 7, 2025	EX-99.1	Selected Condensed Balance Sheets (in thousands) June 30, 2025 December 31, 2024 Assets Cash and cash equivalents $ 149,569 $ 297,263 Total assets $ 250,220 $ 378,318 Total liabilities $ 656,054 $ 631,898 Total stockholders’ deficit $ (405,834 ) $ (2 EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates • Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings report • Net revenues of $39.5 million reported for Q2 • Full-year 2025 revenue guidance of $165 million to $175 million • Company remains focused on path to profitability in 2026 •
August 7, 2025	EX-10.2	Separation Agreement and Release of Claims, dated May 20, 2025, by and between Molly Henderson and the Registrant Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (the “Agreement”) is entered into by and between Molly Henderson (“Executive”) and Phathom Pharmaceuticals, Inc. (the “Company”), effective as of the Effective Date (as defined below). Recitals WHEREAS, Executive is a party to that certain offer letter, dated March 22, 2022, with the Company (th
August 7, 2025	EX-10.1	Separation Agreement and Release of Claims, dated May 18, 2025, by and between Azmi Nabulsi, M.D., M.P.H. and the Registrant Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (the “Agreement”) is entered into by and between Azmi Nabulsi, M.D., M.P.H. (“Executive”) and Phathom Pharmaceuticals, Inc. (the “Company”), effective as of the Effective Date (as defined below). Recitals WHEREAS, Executive is a party to that certain offer letter, dated September 23, 2019, with
June 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2025 PHATHOM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2025 PHATHOM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
June 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 PHATHOM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
June 6, 2025	EX-99.1	June 6, 2025 EX-99.1 Exhibit 99.1 Terrie Curran Chief Executive Officer Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park, NJ 07932 June 6, 2025 Re: Docket No. FDA-2024-P-5703 Dear Ms. Curran: This letter responds to your citizen petition submitted on behalf of Phathom Pharmaceuticals, Inc. (Phathom), and received on December 11, 2024 (Petition). In the Pe
May 1, 2025	EX-10.1	Employment Letter Agreement, dated March 31, 2025, by and between Steven Basta and the Registrant Exhibit 10.1 March 31, 2025 Steve Basta Re: Employment Offer Letter Dear Steve: Phathom Pharmaceuticals, Inc. (the “Company”) is pleased to offer you a position on the terms set forth in this letter (this “Agreement”). • Employment Terms. o Duties; Location. Following the Start Date (as defined below), you shall serve and shall perform such duties as are customarily associated with the position of
May 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2025 PHATHOM PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organiz
May 1, 2025	EX-10.2	Separation Agreement, dated April 2, 2025, by and between Terrie Curran and the Registrant Exhibit 10.2 Separation AGREEMENT and release of claims This Separation Agreement and Release of Claims (the “Agreement”) is entered into by and between Terrie Curran (“Executive”) and Phathom Pharmaceuticals, Inc. (the “Company”), effective as of the Effective Date (as defined below). Recitals WHEREAS, Executive is a party to that certain offer letter dated August 29, 2019, with the Company (the
May 1, 2025	10-Q	10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUT
May 1, 2025	EX-99.1	### Selected Condensed Balance Sheets (in thousands) March 31, 2025 December 31, 2024 Assets Cash and cash equivalents $ 212,315 $ 297,263 Total assets $ 294,208 $ 378,318 Total liabilities $ 632,584 $ 631,898 Total stockholders’ deficit $ (338,376 ) Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update • VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers • Net revenues of $28.5 million reported for Q1 • Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds • Str
April 23, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 23, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ki UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  De
April 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2025 PHATHOM PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
April 3, 2025	S-8	As filed with the Securities and Exchange Commission on April 3, 2025 S-8 As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.
April 3, 2025	EX-10.1	Phathom Pharmaceuticals, Inc. 2025 Employment Inducement Incentive Award Plan and related forms of stock option, and restricted stock unit and performance stock unit agreements thereunder. Exhibit 10.1 PHATHOM PHARMACEUTICALS, INC. 2025 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Arti
April 3, 2025	EX-FILING FEES	Filing Fee Table EX-FILING FEES EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Phathom Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registrati
April 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 PHATHOM PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
March 6, 2025	EX-19	Phathom Pharmaceuticals, Inc. Insider Trading Compliance Policy and Procedures Exhibit 19 Phathom Pharmaceuticals, Inc. Insider Trading Compliance Policy and Procedures (as of May 23, 2024) Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to ot
March 6, 2025	S-8	Power of Attorney (see signature page) As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
March 6, 2025	EX-99.1	Selected Condensed Balance Sheets (in thousands) December 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 297,263 $ 381,393 Total assets $ 378,318 $ 413,842 Total liabilities $ 631,898 $ 486,601 Total stockholders’ deficit $ (253,580 ) Exhibit 99.1 Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3 • Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a
March 6, 2025	EX-4.8	Description of Registered Securities Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Phathom Pharmaceuticals, Inc. (“we,” “us” and “our”) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock General The following description
March 6, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Phathom Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Eq
March 6, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39094 PHATHOM PHARMA
March 6, 2025	EX-10.30	Joinder Agreement dated December 23, 2024 by and among CO Finance III LVS LX LP and the Registrant Exhibit 10.30 JOINDER AGREEMENT This Joinder Agreement is dated as of December 23rd, 2024 (“Joinder Agreement”), by OC III LVS LX LP (the “Additional Investor”). All capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Financing Agreement (as defined below). WHEREAS, Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the In
March 6, 2025	EX-24.1	Power of Attorney Exhibit 24.1 LIMITED POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Molly Henderson, each of whom are officers of Phathom Pharmaceuticals, Inc. (the “Company”), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act with
March 6, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2025 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
December 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2024 PHATHOM PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
November 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 PHATHOM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
November 7, 2024	EX-10.1	Letter Agreement to Vonoprazan Commercial Supply Agreement, dated September 4, 2024, by and among Evonik Operations GmbH and the Registrant Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE PHATHOM PHARMACEUTICALS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO PHATHOM PHARMACEUTICALS, INC. IF PUBLICLY DISCLOSED. 4 September 2024 Phathom Pharmaceuticals, Inc Theresa Ledbetter 100 Campus Drive, Suite 102 Evonik Cor
November 7, 2024	EX-99.1	Selected Condensed Balance Sheets (in thousands) September 30, 2024 December 31, 2023 Assets Cash and cash equivalents $ 334,678 $ 381,393 Total assets $ 387,044 $ 413,842 Total liabilities $ 574,156 $ 486,601 Total stockholders’ deficit $ (187,112 ) Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates • Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increase • Over 143,000 prescriptions filled for VOQUEZNA® (vonoprazan) products, launch to date, a 138% increase since last quarterly r
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMA
August 22, 2024	SC 13D/A	PHAT / Phathom Pharmaceuticals, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of P
August 19, 2024	EX-4.1	Form of Pre-Funded Warrant to purchase common stock Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK PHATHOM PHARMACEUTICALS, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2024 Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its regi
August 19, 2024	EX-1.1	Underwriting Agreement, dated August 19, 2024, by and among Phathom Pharmaceuticals, Inc. and Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein Exhibit 1.1 Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase Shares of Common Stock Underwriting Agreement August 19, 2024 Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated Guggenheim Securities, LLC As representatives of the several Underwriters named in Schedule I hereto, c/o Evercore Group L.L.C. 55 East 52nd Street New York, N
August 19, 2024	EX-99.1	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants Exhibit 99.1 Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants Florham Park, N.J., August 19, 2024 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares o
August 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2024 PHATHOM PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or org
August 19, 2024	424B5	8,695,652 Shares of Common Stock Pre-Funded Warrants to Purchase 2,608,922 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275431 PROSPECTUS SUPPLEMENT (to Prospectus dated November 17, 2023) 8,695,652 Shares of Common Stock Pre-Funded Warrants to Purchase 2,608,922 Shares of Common Stock We are offering 8,695,652 shares of our common stock in this offering. We are also offering, in lieu of shares of common stock to certain investors that so choos
August 19, 2024	FWP	Common Stock Pre-Funded Warrants to Purchase Common Stock FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated August 19, 2024 Relating to Prospectus Dated November 17, 2023 Registration Statement No.
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTI
August 8, 2024	EX-99.1	Selected Condensed Balance Sheets (in thousands) June 30, 2024 December 31, 2023 Assets Cash and cash equivalents $ 276,237 $ 381,393 Total assets $ 319,376 $ 413,842 Total liabilities $ 553,205 $ 486,601 Total stockholders’ deficit $ (233,829 ) $ (7 Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly report • Net revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% inc
August 8, 2024	EX-10.1	Amended and Restated Non-Employee Director Compensation Program Exhibit 10.1 PHATHOM PHARMACEUTICALS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (effective as of May 23, 2024) Non-employee members of the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopt
August 8, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
July 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2024 PHATHOM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
June 14, 2024	EX-97	Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 PHATHOM PHARMACEUTICALS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Phathom Pharmaceuticals, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Sub
June 14, 2024	EX-4.8	Description of Registered Securities Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Phathom Pharmaceuticals, Inc. (“we,” “us” and “our”) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock General The following description
June 14, 2024	CORRESP	********* 12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh June 14, 2024 Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Silicon Valley VIA EDGAR Hong Kong Singapore Houston Tel Aviv London Tokyo U.S. Securities
June 14, 2024	EX-24.1	Power of Attorney Exhibit 24.1 LIMITED POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Molly Henderson, each of whom are officers of Phathom Pharmaceuticals, Inc. (the “Company”), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act with
June 14, 2024	EX-10.28	Phathom Pharmaceuticals Inc. 2024 Bonus Plan Exhibit 10.28 PHATHOM PHARMACEUTICALS BONUS PLAN Effective January 1, 2024 INTRODUCTION AND PURPOSE The Phathom Pharmaceuticals (“Phathom” or the “Company”) Bonus Plan (the “Plan”) is designed to reward eligible employees for the achievement of corporate objectives, as well as measured individual objectives that are consistent with and support the overall corporate objectives. Since cooperation be
June 14, 2024	EX-10.26	First Amendment to the Commercial Supply Agreement, dated as of December 6, 2023, by and among Catalent Pharma Solutions, LLC and the Registrant CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
June 14, 2024	EX-10.27	Fourth Amendment to the Loan and Security Agreement, dated December 14, 2023, by and among Hercules Capital and the Registrant Exhibit 10.27 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of December 14, 2023, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation (“Phathom”), each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (together with Phathom, individually
June 14, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
June 14, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-3909
June 6, 2024	SC 13D/A	PHAT / Phathom Pharmaceuticals, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of P
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 PHATHOM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUT
May 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organiz
May 9, 2024	EX-99.1	Selected Condensed Balance Sheets (in thousands) March 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 322,229 $ 381,393 Total assets $ 356,499 $ 413,842 Total liabilities $ 505,002 $ 486,601 Total stockholders’ deficit $ (148,503 ) $ ( Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report • Net revenues of $1.9 million reported for the first full quarter of launch • Cigna Healthcare recently added VOQUEZNA tablets to its formularies, bro
April 12, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ki UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  De
April 12, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 10, 2024	SC 13D/A	PHAT / Phathom Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo MO 103-8668 Yoshihiro N
April 1, 2024	SC 13D/A	PHAT / Phathom Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo MO 103-8668 Yoshihiro N
March 7, 2024	EX-10.28	Phathom Pharmaceuticals Inc. 2024 Bonus Plan Exhibit 10.28 PHATHOM PHARMACEUTICALS BONUS PLAN Effective January 1, 2024 INTRODUCTION AND PURPOSE The Phathom Pharmaceuticals (“Phathom” or the “Company”) Bonus Plan (the “Plan”) is designed to reward eligible employees for the achievement of corporate objectives, as well as measured individual objectives that are consistent with and support the overall corporate objectives. Since cooperation be
March 7, 2024	EX-24.1	Power of Attorney Exhibit 24.1 LIMITED POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Molly Henderson, each of whom are officers of Phathom Pharmaceuticals, Inc. (the “Company”), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act with
March 7, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39094 PHATHOM PHARMA
March 7, 2024	EX-4.8	Description of Registered Securities Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Phathom Pharmaceuticals, Inc. (“we,” “us” and “our”) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock General The following description
March 7, 2024	EX-10.26	First Amendment to the Commercial Supply Agreement, dated as of December 6, 2023, by and among Catalent Pharma Solutions, LLC and the Registrant CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
March 7, 2024	EX-10.27	Fourth Amendment to the Loan and Security Agreement, dated December 14, 2023, by and among Hercules Capital and the Registrant Exhibit 10.27 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of December 14, 2023, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation (“Phathom”), each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (together with Phathom, individually
March 7, 2024	EX-97	Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 PHATHOM PHARMACEUTICALS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Phathom Pharmaceuticals, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Sub
March 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
March 7, 2024	EX-99.1	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Exhibit 99.1 Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter • Early physician prescribing demonstrates strong demand for VOQUEZNA • Secured expa
February 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2024 PHATHOM PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2024 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
February 12, 2024	SC 13G/A	PHAT / Phathom Pharmaceuticals, Inc. / Carlyle Group Inc. - SC 13G/A Passive Investment SC 13G/A 1 d766962dsc13ga.htm SC 13G/A ITEM 1. Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par
February 12, 2024	EX-24	POWER OF ATTORNEY EX-24 2 d766962dex24.htm EX-24 Exhibit 24 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick,
February 9, 2024	SC 13G/A	PHAT / Phathom Pharmaceuticals, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Phathom Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat
January 26, 2024	SC 13G/A	PHAT / Phathom Pharmaceuticals, Inc. / Medicxi Growth I LP - SC 13G/A Passive Investment SC 13G/A 1 d930770dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) January 24, 2024 (Date of Event Which Requires Filing of this Statemen
January 26, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 d930770dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The unders
January 25, 2024	SC 13D/A	PHAT / Phathom Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo MO 103-8668 Yoshihiro N
January 25, 2024	EX-1	STOCK PURCHASE AGREEMENT EX-1 2 exhibit1012524.htm EX-1 Exhibit 1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of January 24, 2024 (the “Effective Date”), by and among Medicxi IV LP, a Jersey limited partnership (“Medicxi IV”), Medicxi Co-Invest IV LP, a Jersey limited partnership (“Medicxi Co-Invest”) (Medicxi IV and Medicxi Co-Invest each being a “Purchaser” and together being the
December 15, 2023	EX-3.2	Amended and Restated Bylaws (marked version) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PHATHOM PHARMACEUTICALS, INC. (a Delaware corporation) As amended and restated September 22, 2020December 13, 2023 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTEREDOFFICE 1 1.2 OTHEROFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACEOF MEETINGS 1 2.2 ANNUALMEETING 1 2.3 SPECIALMEETING 1 2.4 ADVANCENOTICE PROCEDURES FOR BUSINESS
December 15, 2023	EX-3.1	Amended and Restated Bylaws, effective as of December 13, 2023 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PHATHOM PHARMACEUTICALS, INC. (a Delaware corporation) As amended and restated December 13, 2023 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEF
December 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2023 PHATHOM PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
December 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2023 PHATHOM PHARMAC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
December 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2023 PHATHOM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
November 28, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 28, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
November 15, 2023	CORRESP	Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 November 15, 2023 VIA EDGAR Alan Campbell Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Phathom Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-275431 To the addressee set forth above: Pursuant
November 9, 2023	EX-99.1	Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates • VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major innovation in the U.S. Erosive GERD market in over 30 years • Commercial availability of VOQUEZNA for Erosi
November 9, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Phathom Pharmaceuticals, Inc.
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMA
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
November 9, 2023	EX-5.3	Consent of Latham & Watkins LLP (included in Exhibit 5.3) EX-5.3 Exhibit 5.3 12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris November 9, 2023 Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Silicon Valley Hong Kong Singapore Houston Tel Aviv London Tokyo Los
November 9, 2023	S-3	As filed with the Securities and Exchange Commission on November 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.
November 9, 2023	EX-4.9	Form of Indenture Exhibit 4.9 PHATHOM PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Est
November 1, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
October 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 PHATHOM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
September 26, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or
August 21, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or org
August 10, 2023	EX-10.1	First Amendment to Vonoprazan Commercial Supply Agreement, dated August 1, 2022, by and among Evonik Operations GmbH and the Registrant Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” AMENDMENT NO. 1 TO VONOPRAZAN COMMERCIAL SUPPLY AGREEMENT THIS AMENDMENT NO. 1 TO THE VONOPRAZAN COMMERCIAL SUPPLY AGREEMENT is dated as of May 1, 2023 (“Amendment No
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 PHATHOM PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or org
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTI
August 10, 2023	EX-99.1	Phathom Pharmaceuticals Reports Second Quarter 2023 Results EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2023 Results • Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2023 by the U.S. Food and Drug Administration (FDA) • U.S. commercial launch for H. pylori and Erosive GERD planned for Q4 2023 • Successfully completed Phase 3
August 10, 2023	EX-10.2	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 PHATHOM PHARMACEUTICALS, INC. AMENDED AND RESTATED Non-Employee DIRECTOR COMPENSATION PROGRAM (effective as of May 25, 2023) Non-employee members of the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopt
July 17, 2023	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO AMENDMENT NO. 1 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Phathom Pharmaceuticals, Inc. (Name of Subject Compan SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO AMENDMENT NO. 1 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Phathom Pharmaceuticals, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 71722W1
July 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2023 PHATHOM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
June 15, 2023	EX-99.A112	SUMMARY TERM SHEET AND QUESTIONS AND ANSWERS EX-99.(a)(1)(xii) Exhibit (a)(1)(xii) SUMMARY TERM SHEET AND QUESTIONS AND ANSWERS The following are important terms and answers to some of the questions that you may have about the Option Exchange. You should carefully read this entire Offer to Exchange, the accompanying announcement emails from Phathom, and the Election Terms and Conditions, together with the associated instructions and agreemen
June 15, 2023	EX-99.A11	PHATHOM PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR RESTRICTED STOCK UNITS THIS OFFER TO EXCHANGE AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTERN TIME, ON JULY 14, 2023, UNLESS THE OFFER IS EXTENDED EX-99.(a)(1)(i) Exhibit (a)(1)(i) PHATHOM PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR RESTRICTED STOCK UNITS THIS OFFER TO EXCHANGE AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. EASTERN TIME, ON JULY 14, 2023, UNLESS THE OFFER IS EXTENDED Phathom Pharmaceuticals, Inc., a Delaware corporation (the “Company,” “Phathom,” “our,” “us” or “we”), is offering eligi
June 15, 2023	EX-99.A16	Option Exchange EX-99.(a)(1)(vi) Exhibit (a)(1)(vi) Option Exchange Phathom Pharmaceuticals, Inc. (“Phathom”) has received your election via Phathom’s Option Exchange website by which you elected to accept or reject Phathom’s offer to exchange certain outstanding stock options for new restricted stock units (“RSUs”) subject to the terms and conditions of the Offer to Exchange (the “Option Exchange”). Your electio
June 15, 2023	EX-99.A13	Email to All Eligible Participants EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) Email to All Eligible Participants To: Eligible Phathom Employees and Consultants From: Joe Hand, Chief Administrative Officer Date: June 15, 2023 Subject: Details Regarding Phathom’s Option Exchange Attachments: 1. Offer to Exchange Certain Outstanding Stock Options for Restricted Stock Units 2. Election Terms and Conditions Dear Colleagues, Following Terrie’
June 15, 2023	EX-99.A12	EMAIL TO ALL EMPLOYEES AND CONSULTANTS FROM TERRIE CURRAN EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) EMAIL TO ALL EMPLOYEES AND CONSULTANTS FROM TERRIE CURRAN To: Eligible Phathom Employees and Consultants From: Terrie Curran, President & CEO Date: June 15, 2023 Subject: Announcing Phathom’s Option Exchange Program for Options with a strike price above $30 Dear Colleagues, We have made phenomenal progress advancing our mission and vision of building the leading
June 15, 2023	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Phathom Pharmaceuticals, Inc. (Name of Subject Company (Issuer) and F SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Phathom Pharmaceuticals, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 71722W107 (CUSIP Number o
June 15, 2023	EX-99.A14	Second Email to All Eligible Participants EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) Second Email to All Eligible Participants To: Eligible Phathom Employees and Consultants From: Joe Hand, Chief Administrative Officer Date: [ ], 2023 Subject: Important Reminders Regarding Phathom’s Option Exchange Dear Colleagues, [Following the Option Exchange Information Session, I wanted to send a recap of some important items covered.] As a reminder, this i
June 15, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 PHATHOM PHARMACEUTI SC TO-C 1 d523149dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other ju
June 15, 2023	EX-99.A15	PHATHOM PHARMACEUTICALS, INC. ELECTION TERMS AND CONDITIONS EX-99.(a)(1)(v) Exhibit (a)(1)(v) PHATHOM PHARMACEUTICALS, INC. ELECTION TERMS AND CONDITIONS BY YOUR ELECTION TO PARTICIPATE PURSUANT TO THE “ELECTION FORM” PAGE OF THE OPTION EXCHANGE WEBSITE, YOU AGREE TO ALL TERMS OF THE OPTION EXCHANGE AS SET FORTH IN THE OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR RESTRICTED STOCK UNITS, DATED JUNE 15, 2023 (AS IT MAY BE AMENDED AND SUPPLEMENTED
June 15, 2023	EX-99.A111	Phathom PHARMACEUTICALS Option Exchange Commencement Date: June 15, 2023 Expiration Time: July 14, 2023 at 11:59pm Eastern Time We are offering you the opportunity to exchange some or all of your eligible stock options, as described in the offer to e EX-99.(a)(1)(xi) Exhibit (a)(1)(xi) Phathom PHARMACEUTICALS Option Exchange Commencement Date: June 15, 2023 Expiration Time: July 14, 2023 at 11:59pm Eastern Time We are offering you the opportunity to exchange some or all of your eligible stock options, as described in the offer to exchange certain outstanding stock options for restricted stock units (the “offer to exchange”), for a lesser numbe
June 15, 2023	EX-99.A17	Form of First Reminder Email Communication EX-99.(a)(1)(vii) Exhibit (a)(1)(vii) Form of First Reminder Email Communication According to our records, you have not yet submitted an election for your eligible options. This email is to remind you that July 14, 2023, at 11:59 p.m. Eastern Time is the final deadline to participate in the option exchange. The option exchange deadline will be strictly enforced, so we encourage you to give yoursel
June 15, 2023	EX-99.A113	OPTION EXCHANGE OVERVIEW June 2023 1 EX-99.(a)(1)(xiii) Exhibit (a)(1)(xiii) OPTION EXCHANGE OVERVIEW June 2023 1 Background & Phathom’s Today’s topics Compensation Philosophy regarding the Option Stock Options and RSUs Exchange Option Exchange Program Details Making Your Elections via the Option Exchange Portal Q&A and FAQs Background & Phathom’s Compensation Philosophy 3 Announcing voluntary underwater option exchange program Emplo
June 15, 2023	EX-FILING FEES	Calculation of Filing Fee Table SC TO-I (Form Type) Phathom Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $12,575,989.0 EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table SC TO-I (Form Type) Phathom Pharmaceuticals, Inc.
June 15, 2023	EX-99.A18	Form of Second Reminder Email Communication EX-99.(a)(1)(viii) Exhibit (a)(1)(viii) Form of Second Reminder Email Communication According to our records, you have not yet submitted an election for your eligible options. This email is to remind you that July 14, 2023, at 11:59 p.m. Eastern Time is the final deadline to participate in the option exchange. The option exchange deadline will be strictly enforced, so we encourage you to give your
June 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 PHATHOM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
June 15, 2023	EX-99.A110	Form of Notice Email to Eligible Employees and Consultants Regarding Expiration of Offering Period EX-99.(a)(1)(x) Exhibit (a)(1)(x) Form of Notice Email to Eligible Employees and Consultants Regarding Expiration of Offering Period As of July 14, 2023, we closed the Phathom Pharmaceuticals, Inc. Offer to Exchange Certain Outstanding Stock Options for Restricted Stock Units. If you were an eligible employee or consultant for purposes of the option exchange who properly elected to participate in
June 15, 2023	EX-99.A19	Form of Final Reminder Email Communication EX-99.(a)(1)(ix) Exhibit (a)(1)(ix) Form of Final Reminder Email Communication According to our records, you have not yet submitted an election for your eligible options. This email is a final reminder that today, July 14, 2023, at 11:59 p.m. Eastern Time is the deadline to participate in the option exchange. The option exchange deadline will be strictly enforced and this is your last chance to ma
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 PHATHOM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
May 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 PHATHOM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 30, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of the State of Delaware on May 26, 2023 EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PHATHOM PHARMACEUTICALS, INC. (a Delaware corporation) Phathom Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: FIRST: The name of the corporation is Phathom Pharm
May 26, 2023	EX-99.A	Page 2 EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Common Stock of Phathom Pharmaceuticals, Inc. Date: May 26, 2023 FRAZIER LIFE SCIENCES IX, L.P. By FHMLS IX, L.P., its ge
May 26, 2023	SC 13D/A	PHAT / Phathom Pharmaceuticals Inc / Frazier Life Sciences Public Fund, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of P
May 24, 2023	EX-99.1	### EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock Florham Park, N.J., May 23, 2023 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its
May 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2023 PHATHOM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 24, 2023	EX-99.2	### EX-99.2 Exhibit 99.2 Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock Florham Park, N.J., May 23, 2023 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stoc
May 24, 2023	EX-1.1	Underwriting Agreement, dated May 23, 2023, by and among Phathom Pharmaceuticals, Inc. and Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein Exhibit 1.1 Phathom Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement May 23, 2023 Jefferies LLC Evercore Group L.L.C. As representatives of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Ladies and Gentlemen: Phathom Pharma
May 24, 2023	424B5	11,125,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250014 PROSPECTUS SUPPLEMENT (to Prospectus dated November 17, 2020) 11,125,000 Shares Common Stock We are offering 11,125,000 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Select Market under the symbol “PHAT.” On May 23, 2023, the last reported sale price of our common sto
May 23, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 23, 2023	424B5	SUBJECT TO COMPLETION, DATED MAY 23, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250014 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospe
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUT
May 10, 2023	EX-10	Third Amendment to the Loan and Security Agreement, dated May 9, 2023, by and among Hercules Capital and the Registrant Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 9, 2023, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation (“Phathom”), each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (together with Phathom, individually or colle
May 10, 2023	EX-4	Form of Warrant to purchase stock issuable pursuant to the Loan and Security Agreement, as amended, by and between the Registrant and Hercules Capital, Inc. Exhibit 4.6 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS
May 10, 2023	EX-99.1	Phathom Pharmaceuticals Reports First Quarter 2023 Results Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2023 Results FLORHAM PARK, N.J., May 10, 2023 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress. “This quarter,
May 10, 2023	EX-4	First Amendment to Warrant to purchase stock issued to Hercules Capital, dated May 9, 2023 Exhibit 4.5 FIRST AMENDMENT TO WARRANT THIS FIRST AMENDMENT TO WARRANT (this “Amendment”), dated as of May 9, 2023, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation (“Company”) and the several banks and other financial institutions or entities from time to time party to the Loan Agreement (collectively, referred to as the “Warrantholders”). SECTION 1 Definitions;
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 PHATHOM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 5, 2023	SC 13D/A	PHAT / Phathom Pharmaceuticals Inc / Frazier Life Sciences Public Fund, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of P
April 13, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2023 PHATHOM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
March 31, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
March 9, 2023	EX-24	POWER OF ATTORNEY EX-24 Exhibit 24 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings.
March 9, 2023	EX-99	JOINT FILING AGREEMENT EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G.
March 9, 2023	SC 13G	PHAT / Phathom Pharmaceuticals Inc / Carlyle Group Inc. - SC 13G Passive Investment SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of
February 28, 2023	EX-10	Joinder and Waiver agreement dated October 31, 2022 by and among Hercules Capital, CO Finance LVS XXXVII LLC and the Registrant Exhibit 10.37 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” JOINDER AND WAIVER AGREEMENT This JOINDER AND WAIVER AGREEMENT, dated as of October 31, 2022 (this “Joinder Agreement”), is entered into by and among Phathom Pharmac
February 28, 2023	EX-4	Description of Registered Securities EX-4 2 phat-ex46.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Phathom Pharmaceuticals, Inc. (“we,” “us” and “our”) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock Genera
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39094 PHATHOM PHARMA
February 28, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
February 28, 2023	EX-99.1	Selected Condensed Balance Sheets (in thousands) December 31, 2022 December 31, 2021 Assets Cash and cash equivalents $ 155,385 $ 183,259 Total assets $ 164,810 $ 189,431 Total liabilities $ 239,624 $ 117,275 Total stockholders’ equity (deficit) $ (7 EX-99.1 2 d413841dex991.htm EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update • Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications FLORHAM PARK, N.J., February 28, 2023 — Phatho
February 28, 2023	EX-24	Power of Attorney Exhibit 24.1 LIMITED POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Larry Miller, each of whom are officers of Phathom Pharmaceuticals, Inc. (the “Company”), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act without
February 14, 2023	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994212013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 71722W107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th
February 10, 2023	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / Flynn James E Passive Investment SC 13G/A 1 e618276sc13ga-pp.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Decembe
February 9, 2023	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Phathom Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 71722W107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 PHATHOM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
February 2, 2023	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Phathom Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 31, 2023	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / Medicxi Growth I LP - SC 13G/A Passive Investment SC 13G/A 1 d335826dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stateme
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 PHATHOM PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or org
January 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 PHATHOM PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or org
November 9, 2022	EX-10.2	Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant Exhibit 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of September 26, 2022, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation, each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (individually or collectively, as the context ma
November 9, 2022	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-
November 9, 2022	EX-99.1	Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates • Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 • Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total
November 9, 2022	EX-10.1	Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022 Exhibit 10.1 VONOPRAZAN COMMERCIAL SUPPLY AGREEMENT This Vonoprazan Commercial Supply Agreement (this ?Agreement?) effective as of August 1, 2022 (?Effective Date?) between Phathom Pharmaceuticals, Inc, located at 100 Campus Drive, Suite 102, Florham Park, NJ 07932, USA (?Purchaser?), and Evonik Operations GmbH, a limited liability company located at Rodenbacher Chaussee 4, 63457 Hanau (Wolfgang),
November 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 PHATHOM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMA
November 8, 2022	EX-10.1	Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022 Exhibit 10.1 VONOPRAZAN COMMERCIAL SUPPLY AGREEMENT This Vonoprazan Commercial Supply Agreement (this ?Agreement?) effective as of August 1, 2022 (?Effective Date?) between Phathom Pharmaceuticals, Inc, located at 100 Campus Drive, Suite 102, Florham Park, NJ 07932, USA (?Purchaser?), and Evonik Operations GmbH, a limited liability company located at Rodenbacher Chaussee 4, 63457 Hanau (Wolfgang),
November 8, 2022	EX-10.2	Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant. Exhibit 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of September 26, 2022, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation, each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (individually or collectively, as the context ma
November 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Phathom Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Phathom Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation) (Com
November 1, 2022	EX-99.1	Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in EX-99.1 Exhibit 99.1 Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement • Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital • Provides agreement for additional $15 million upon
October 24, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2022 PHATHOM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
September 29, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Phathom Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation) (C
September 26, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or
September 26, 2022	SC 13D/A	PHAT / Phathom Pharmaceuticals Inc / Frazier Life Sciences IX, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of P
September 23, 2022	SC 13G	PHAT / Phathom Pharmaceuticals Inc / Flynn James E Passive Investment SC 13G 1 e621942sc13g-pp.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) September 2
August 11, 2022	EX-99.A	Page 2 EX-99.A 2 d366284dex99a.htm EX-A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Common Stock of Phathom Pharmaceuticals, Inc. Date: August 11, 2022 FRAZIER LIFE SCIENCES IX, L.
August 11, 2022	SC 13D/A	PHAT / Phathom Pharmaceuticals Inc / Frazier Life Sciences IX, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of P
August 4, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
August 2, 2022	EX-10.2	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan Exhibit 10.2 PHATHOM PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the ?Plan?) of Phathom Pharmaceuticals, Inc. (the ?Company?). The Company hereby grants to th
August 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
August 2, 2022	EX-10.6	Transition and Separation Agreement and Release of Claims, dated April 5, 2022, by and between the Registrant and Anthony Guzzo Exhibit 10.6 TRANSITION and Separation AGREEMENT and release of claims This Transition and Separation Agreement and Release of Claims (the ?Agreement?) is entered into by and among Anthony Guzzo (?Executive?) and Phathom Pharmaceuticals, Inc. (the ?Company?). Recitals WHEREAS, Executive currently serves as the Chief Accounting Officer of the Company and has expressed an intention to voluntarily re
August 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTI
August 2, 2022	EX-99.1	Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates ? Erosive Esophagitis (EE) New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA) with Prescription Drug User Fee Act (PDUFA) action date of January 11, 2023; if approved, targeting US launch in Q1 2023 ? VOQUEZNA DUAL and TRIPLE PAK approved by FDA for treatment
August 2, 2022	EX-10.4	First Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant Exhibit 10.4 CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of May 3, 2022, is entered into by and among PHATHOM PHARMACEUTICALS, INC., a Delaware corporation, each of its Subsidiaries from time to time party to the Loan Agreement (as defined below) as borrower (individually or collectively, as
August 2, 2022	EX-10.5	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.5 PHATHOM PHARMACEUTICALS, INC. AMENDED AND RESTATED Non-Employee DIRECTOR COMPENSATION PROGRAM (effective as of May 25, 2022) Non-employee members of the board of directors (the ?Board?) of Phathom Pharmaceuticals, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopt
August 2, 2022	EX-10.3	Revenue Interest Financing Agreement, dated May 3, 2022, by and among NovaQuest Capital Management, Sagard Holding Manager, Hercules Capital and the Registrant Exhibit 10.3 Revenue Interest Financing Agreement By and Among Phathom Pharmaceuticals, Inc., as the Company and The Entities Set Forth on Schedule 1.1, as Investors Dated as of May 3, 2022 Table of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Certain Interpretations 18 ARTICLE 2 REVENUE INTEREST FINANCING 20 Section 2.1 Payment of the Investment Amount 20 Section 2.
May 27, 2022	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 25, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 16, 2022	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* PHATHOM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) May 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUT
May 10, 2022	EX-99.1	Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates ? U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA? TRIPLE PAK? (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA? DUAL PAK? (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults ? Up to $260 million revenue interest fi
May 10, 2022	EX-10.1	Employment Letter Agreement, dated March 22, 2022, by and between Molly Henderson and the Company Exhibit 10.1 March 22, 2022 Molly Henderson Basking Ridge, New Jersey [email protected] Re: Employment Offer Letter Dear Molly: Phathom Pharmaceuticals, Inc. (the ?Company?) is pleased to offer you a position on the terms set forth in this letter (this ?Agreement?). ? EMPLOYMENT TERMS. o DUTIES. Following the Start Date (as defined below), you shall serve as the Company?s Chief Financial and B
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 4, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organiz
May 4, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 Phathom Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation) (Commissi
May 4, 2022	EX-99.1	Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital Exhibit 99.1 Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital ? Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) ? Provides capital for launch of vonoprazan in H. pylori and EE, if approved, in addition to Phase 3 program in non-erosive
April 26, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 26, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
April 12, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 phat-def14a-2022proxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Onl
April 12, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
March 14, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
March 10, 2022	EX-FILING FEES	Filing Fee Table EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Phathom Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equi
March 10, 2022	S-8	As filed with the Securities and Exchange Commission on March 10, 2022 As filed with the Securities and Exchange Commission on March 10, 2022 Registration No.
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organ
March 1, 2022	EX-10.30	First Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 4, 2021 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39094 PHATHOM PHARMA
March 1, 2022	EX-24.1	Power of Attorney Exhibit 24.1 LIMITED POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person or entity whose signature appears below constitutes, designates and appoints each of Terrie Curran and Larry Miller, each of whom are officers of Phathom Pharmaceuticals, Inc. (the ?Company?), as its true and lawful attorneys-in-fact and agent, each with power of substitution, with full power to act without
March 1, 2022	EX-99.1	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress Exhibit 99.1 Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress FLORHAM PARK, N.J., March 1, 2022 ? Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial resul
March 1, 2022	EX-4.6	Description of Registered Securities Exhibit 4.6 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Phathom Pharmaceuticals, Inc. (?we,? ?us? and ?our?) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. Description of Common Stock General The following description
February 14, 2022	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - PHATHOM PHARMACEUTICALS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PHATHOM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
February 14, 2022	SC 13G	PHAT / Phathom Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2022	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / Yamada Tadataka - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of
February 10, 2022	SC 13G/A	PHAT / Phathom Pharmaceuticals Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Phathom Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 71722W107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 10, 2022	SC 13G	PHAT / Phathom Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Phathom Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 71722W107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1
February 9, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
January 25, 2022	EX-10.1	Form of Restricted Stock Unit Agreement under the 2019 Incentive Award Plan. Exhibit 10.1 PHATHOM PHARMACEUTICALS, INC. 2019 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the ?Plan?) of Phathom Pharmaceuticals, Inc. (the ?Company?). The Company hereby grants to th
January 25, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2022 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
November 12, 2021	SC 13D/A	PHAT / Phathom Pharmaceuticals Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
November 8, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
November 8, 2021	EX-10.1	Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 17, 2021 and is entered into by and among Phathom Pharmaceuticals, Inc., a Delaware corporation, each of its Subsidiaries from time to time party hereto as borrower (individually or collectively, as the context may require, ?Borrower?), and the several banks and other financial institutions
November 8, 2021	EX-10.2	Warrant to purchase stock issued to Hercules Capital, dated September 17, 2021 Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
November 8, 2021	EX-99.1	Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates ? Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May 3, 2022 ? U.S. launch for both vonoprazan-based treatment regimen
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMA
October 26, 2021	424B5	SUBJECT TO COMPLETION, DATED OCTOBER 26, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250014 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus a
October 18, 2021	8-K	Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or or
September 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or
September 20, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or
September 8, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or o
August 10, 2021	EX-10.5	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.5 PHATHOM PHARMACEUTICALS, INC. AMENDED AND RESTATED Non-Employee DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Phathom Pharmaceuticals, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). This Program has been adopted under the Company?s 2019 Inc
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or org
August 10, 2021	EX-10.4	Commercial Supply Agreement with Catalent Pharma Solutions, LLC entered into on July 2, 2021 Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICATED BY ?[***].? EXECUTION VERSION COMMERCIAL SUPPLY AGREEMENT ((Vonoprazan Fumarate) finished packaged tablets) This Commercial Supply Agreement (?Agreement?) is made as of this 30th
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTI
August 10, 2021	EX-99.1	Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones ? Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021 ? Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling ahead of schedule with topline data now expected in t
August 10, 2021	EX-10.2	Third Amendment to the Loan and Security Agreement, dated May 26, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant Exhibit 10.2 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 26th day of May, 2021, by and among (a) SILICON VALLEY BANK, a California corporation (?SVB?), in its capacity as administrative agent and collateral agent (?Agent?), (b) SILICON VALLEY BANK, a California corporation, as a lender, (c) SVB INNOVATIO
August 10, 2021	EX-10.1	SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 11th day of March, 2021, by and among (a) SILICON VALLEY BANK, a California corporation (?SVB?), in its capacity as administrative agent and collateral agent (?Agent?), (b) SILICON VALLEY BANK, a California corporation, as a lender, (c) SVB INNOV
August 10, 2021	EX-10.3	Separation and Release Agreement dated June 4, 2021, between the Registrant and Todd Branning Exhibit 10.3 Separation AGREEMENT and release of claims This Separation Agreement and Release of Claims (the ?Agreement?) is entered into by and among Todd Branning (?Executive?) and Phathom Pharmaceuticals, Inc. (the ?Company?), effective as of the Effective Date (as defined below). Recitals WHEREAS, Executive is a party to that certain offer letter dated June 25, 2020, with the Company (the ?Off
August 5, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or orga
August 5, 2021	EX-99.1	Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka “Tachi” Yamada, M.D. Exhibit 99.1 Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka ?Tachi? Yamada, M.D. FLORHAM PARK, N.J., August 5, 2021 ? Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the sad news that its chairman and founder, Dr. Tachi Y
July 8, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
June 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 25, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2021 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39094 82-4151574 (State or other jurisdiction of incorporation or organi
May 11, 2021	EX-10.1	Second Amendment to the Loan and Security Agreement, dated March 11, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registran Exhibit 10.1 SECOND Amendment to Loan and security agreement This Second Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 11th day of March, 2021, by and among (a) SILICON VALLEY BANK, a California corporation (?SVB?), in its capacity as administrative agent and collateral agent (?Agent?), (b) SILICON VALLEY BANK, a California corporation, as a lender, (c) SVB Innov
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUT
May 11, 2021	EX-99.1	Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates ? Positive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021 ? U.S. Food and Drug Administration (FDA) grants additional qualified infectious disease product (QIDP) designations to vonoprazan-based

PHAT / Phathom Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)